R&D planning
Development plan, preclinical and clinical strategy. Regulatory roadmap and technical gates. Manufacturing and quality, including CMC (chemistry, manufacturing and controls).
BaiOS · The gates almost nobody sets up
Your development plan, with what every decision gate costs and the money that is really there.
That cost stays up to date as the plan moves, and you load the whole plan in one session.
Book a diagnostic sessionRun the free readiness checkFirst call, no cost. You leave with your priorities ranked.
The problem
The science can be brilliant and the project still be a mess.
No plan, no legal structure, and a story that does not survive three questions from an investor. A biotech is not built on good science alone. It is built on decisions taken in the right order.
01
No development plan
Promising scientific data, but no clear development plan.
02
Fronts pulling apart
Science, regulation, market and funding pulling in different directions.
03
No legal structure
No legal structure for the spin-off, the founders, the IP or the contracts.
04
Projections on demand
Financial projections built because a spreadsheet asked for them.
05
Roadmaps without gates
Roadmaps with no gates, no ranked risks and no owners.
06
Not a company yet
A publication is not a company. A patent is not a round.
What we do
Biotech advisory for the decisions you cannot improvise.
We structure the project across three connected services. A bad legal decision hits the funding; a bad market assumption hits the development plan. Nothing here is independent.
Financial planning
Feasibility, market and competition. Business plan, financial model and funding strategy. The narrative an investor reads.
Legal advice
Spin-offs and shareholder agreements. Intellectual property, contracts and licensing. Technology transfer and compliance.
We also produce the scientific communication around it: video, event broadcasting, web design and training material. The science has to land with the investors, partners and regulators who read it.
The decision stack
A bad call on one front moves the other two.
A legal decision changes the investment. A market hypothesis changes the development. A regulatory strategy changes what the company is worth. We do not work them as separate pieces.
The three services
R&D planningPreclinical · CMC · Gates
Financial planningMarket · Runway · Funding
Legal adviceSpin-off · Patents · Contracts
Advisory · the people
Strategic advisory, end to end.
The same three services, in the same order, with a senior name behind each. It runs from the science and its protection to the business case the investor signs.
01
R&D planning
From the promising experiment to the asset roadmap. We sequence the target product profile, the evidence strategy and the regulatory route. It runs from preclinical to first dose in humans.
- Target product profile (TPP)
- Preclinical and evidence plan
- Regulatory roadmap and gate map
- CMC and manufacturing strategy
02
Financial planning
We build the case that raises capital. Market and competition, business model, financial plan and funding strategy. It runs from the public grant to the Series A.
- Feasibility and market analysis
- Business plan and financial model
- Funding strategy (public and private)
- Investor memo, pitch deck and data room
03
Legal advice
We protect the asset and structure the company. Freedom to operate, patents and licensing. Company structure, and the regulatory and data compliance an investor will audit.
- Corporate structure and shareholder agreements
- Spin-off and technology transfer
- IP strategy and patent plan
- Biotech contracts (NDA, CRO, CDMO, licensing)
Programs
Packaged advisory, with a defined scope.
We do not sell blocks of hours. Every program has an objective, a scope and a set of deliverables. You know what you get, and when.
Venture Scan
A fast read of the project: how mature it is in science, law, market and funding. The critical decisions come out ranked.
Venture Blueprint
The development and business plan, sequenced gate by gate. Milestones, risks, costs and owners. Ready to execute.
Legal Biotech Kit
The legal structure that makes the technology fundable: company, shareholder agreement, IP and key contracts.
Investor Readiness Pack
The case an investor signs off. Business plan, financial model and investor memo. Pitch deck and data room.
Maturity & Investability Report
An independent report on the maturity and investability of the asset, with a roadmap to close the gaps.
Fractional PMO
Part-time project direction: the project management office, without a full-time hire. We track milestones, runway and risk, and report to the team and its investors.
Method
How we work.
First we think. Then we structure. Then we execute. We leave the magic to LinkedIn.
Diagnostic
We map the asset, its stage and its legal structure. Then the funding, the risks and the priorities.
Critical decision map
We identify what is actually blocking progress. The block can sit in the science, the law, the money or the market.
Development and business plan
A sequenced plan. It carries milestones and gates, costs and owners, risks and deliverables.
Execution and expert support
We stay on the key calls: development and manufacturing, intellectual property and contracts, funding and investors.
Tracking and reporting
We review progress, runway, milestones and risks. Then we write the reports for the team, the board and its investors.
Ensayo de toxicidad
Preclínico
185 k€
▲ en plazo
Solicitud PCT
Propiedad industrial
32 k€
● pendiente
Reunión de asesoramiento
Regulatorio · AEMPS
Mar ’27
▼ 6 sem.
Cierre de ronda
Inversión · Serie A
2.4 M€
▲ 8 % vs plan
Deliverables
What you get from working with Adbaio.
We do not deliver general recommendations. We deliver the structure to decide and move.
R&D planning
Strategic diagnostic+
Development roadmap+
Preclinical and clinical plan+
Regulatory strategy+
CMC and manufacturing plan+
Risk map+
Financial planning
Business plan+
Financial model+
Runway and scenarios+
Market analysis+
Competitive landscape+
Pitch deck, investor memo and data room+
Periodic progress reports+
Legal advice
Spin-off and company structure+
Shareholder agreements+
IP strategy+
Key contracts+
Team
A hybrid team for a hybrid problem
Building a biotech takes science and regulation, law and business, funding and market. That is why the team is put together the way it is.
RM
Chief scientific officer. Over 25 years in pharma and biotech: drug development, CMC and scientific strategy.
Science · CMC
ÁÍ
Lawyer. Contracts, corporate and R&D law, pharmaceutical and administrative law. Biotech legal support.
Legal · IP
AM
Business development, strategy, market and access. Customer strategy in pharma and biotech.
Business · Market
RÍ
Rubén Íñiguez Pérez
Digital training, audiovisual production and scientific communication.
Digital · Communication
Network of specialist collaborators
- Manish Sharma — Manufacturing · CMC
- Jaume Ruiz — Development · Business
- Karen Sánchez — Legal · Data
- Leire Zúñiga — Clinical trials
- Naiara Pineda — Finance
FAQ
Frequently asked questions
Do you only work with biotech startups?
No. We work with researchers, spin-offs and biotech startups, and with pharma and biotech companies. The projects can be in health, advanced therapies, medical devices or related technologies.
At what stage does it make sense to talk to you?
Early, above all. Before the spin-off, during preclinical, or while you raise funding. The sooner the critical decisions are put in order, the less the chaos costs.
How is an engagement structured?
Through programs with a defined scope and deliverables, or as bespoke support. We almost always start with a diagnostic. It ranks the priorities before you commit to larger work.
Do you help with funding?
Yes. Business plan, financial model and investor narrative. Pitch deck, investor memo and data room. Term sheets, and public or private funding strategy.
Do you handle legal work?
Yes. Corporate structure, spin-offs and shareholder agreements. Intellectual property, contracts and licensing. Technology transfer, sector regulation, data protection and due diligence.
Do you replace the scientific team?
No. We complement it with development judgement and legal structure, market sense and funding. The science stays with the team. We bring the order.
Contact
Have a project and need advice?
Tell us where the project stands. Book a call, or write through the form. We will come back with the next steps.
Promising science and too many loose pieces?
Tell us where the project stands. We will help you work out what it needs to move: development, legal, market or funding.
Book a diagnostic sessionOne call can save months aimed at the wrong question.